<p><div class="KonaFilter image-container display-table float_right"><div><div class="image on-image"><p class="source"><span>AP</span></p><p class="caption">A person administers an injection of insulin.</p></div><p></p></div></div>Insulin has been around since 1923, so it came as a surprise in July 2015 when Cole LePere's doctor told his mother, Janine, to prepare to pay a lot at the pharmacy for it.</p><p>Cole, who was 10, had just been found to have Type 1 diabetes, which commonly affects children. But even the pharmacist was shocked to see the price.</p><p>Over and over, the pharmacist told Janine LePere, "This is really expensive." Each time she would respond, "I know, thanks, but I still need the medicine."</p><p>The pharmacist finally gave the LePeres the supplies - and a bill for $1,550.</p><p>That was after a $350 coupon.</p><p>As lawmakers and the public scrutinize dramatic price increases for other old drugs - most recently with the Mylan-owned EpiPen, which saw its cost go up by 500% in the past nine years - the next flash point may be insulin, a drug both ubiquitous and complicated.</p><p>And the story of why the LePeres are now paying as much as their mortgage payment on insulin, even though they have insurance and even though there are competing drugs on the market, is really the story of what has happened to the healthcare industry in America since the start of the century.</p><h2>The need for insulin</h2><p>The human body produces its own insulin. Some people can't. </p><p>When he got the diagnosis, Cole LePere found himself one of nearly <a href="http://www.diabetes.org/diabetes-basics/statistics/">29.1 million Americans</a> known to have one of the two types of diabetes. Cole's kind, known as Type 1, is an autoimmune disease. His body mistakenly kills so-called beta cells that are supposed to make the body's insulin, a hormone that helps people absorb and process the sugar in food. The roughly <a href="http://www.diabetes.org/diabetes-basics/statistics/">1.25 million</a> people in the US who have Type 1 diabetes need to inject insulin to live. Type 2 diabetes, <a href="https://www.niddk.nih.gov/health-information/diabetes/causes">the more common form</a>, is something that develops either based on genetic or lifestyle choices, and doesn't always require that you need to take insulin.</p><p>These days his mother says she spends $1,100 out of her pocket each month on his diabetes supplies. The list price of the drugs he takes, called Humalog and Lantus and made by the drug companies Eli Lilly and Sanofi Aventis, have risen by about 300% over the past decade.</p><p>Many patients don't pay anything close to that sticker price. Some families Business Insider spoke with had their insulin mostly or entirely covered by insurance.</p><p>But at the same time drug companies were increasing prices for many drugs, insurance plans have been going through their own transformation, leaving more families like the LePeres on the hook for far more of that cost.</p><p>In half a dozen conversations with mothers of children with Type 1 diabetes, we heard stories like Janine LaPere's. The anxieties of these families don't just end with their monthly paycheck. Diabetes is a lifelong disease, and they worry too about what their children will do when they no longer have their parents' insurance covering them.</p><p><div class="KonaFilter image-container display-table float_right"><div><div class="image on-image"><p class="source"><span>Courtesy Janine Lepere</span></p><p class="caption">Janine LePere with her husband and sons (from left, Riley, Cole, and Dylan).</p></div><p></p></div></div></p><h2>Now, you pay</h2><p>One reason Janine LePere is paying so much for insulin is that the LePere family has a high-deductible health plan. Before the insurance company pays a penny toward drugs, she and her husband have to spend $7,000 each year. To make matters worse, that deductible is increasing to $10,000 in December, she says.</p><p>And these plans are rapidly becoming more common. In 2006, <a href="http://healthaffairs.org/healthpolicybriefs/brief_pdfs/healthpolicybrief_152.pdf">only 4% of people</a> who worked were enrolled in a high-deductible health plan. A decade later, that's <a href="https://www.cdc.gov/nchs/data/nhis/earlyrelease/insur201609.pdf">up to 25%</a>. And the amount that people are paying for deductibles is rising as well. A Kaiser Family Foundation survey found that <a href="http://www.businessinsider.com/out-of-pocket-healthcare-payments-skyrocketing-2016-9">deductibles had gone up 63%</a> in the past five years, 10 times the rate of inflation.</p><p>LePere was a salon manager, but she recently went to school to become a nail technician to earn more money to help pay for Cole's medication.</p><p>"This cost problem is yet another headache on top of complicated disease," Dr. Elbert Huang, a primary-care physician who has <a href="http://jama.jamanetwork.com/article.aspx?articleid=2510902#">researched the cost of insulin</a>, told Business Insider.</p><p>High prices particularly affect the US, though some other countries have trouble getting access to the medication in the first place, said Sarah Lucas, the CEO of Beyond Type 1, a nonprofit aimed at helping educate young adults living with Type 1 on how to live with their disease.</p><h2>What's old is new again</h2><p>Given insulin's history, and the fact that more than one company makes it, it might seem odd that prices have been going up so dramatically.</p><p>Researchers first figured out how to manufacture insulin in <a href="https://www.nobelprize.org/educational/medicine/insulin/discovery-insulin.html">animal pancreases</a> back in the 1920s so that it could be injected into people. The doctor who developed it, Dr. Frederick Banting, <a href="https://www.nobelprize.org/educational/medicine/insulin/discovery-insulin.html">won a Nobel Prize</a> for the discovery in 1923.</p><p>Since then, there have been some big changes. In the 1970s, scientists figured out how to use recombinant DNA to manufacture real human insulin, so that it no longer had to come from animals. But in drug years, that is old, and those insulins are still in use.</p><p>The most prescribed types of insulin are called analogues, which are slight variations of human insulin that aim to help diabetics' bodies function more closely to how they would if they were able to produce the insulin themselves.</p><p>This is the kind Cole LePere's doctor prescribed. A 2011 <a href="http://www.who.int/selection_medicines/committees/expert/18/applications/Insulin_review.pdf">World Health Organization review</a>, however, did not find that analogue insulins had any advantage over human insulins, and at about twice the cost, the WHO said they're not worth the price.</p><p>Drug companies have a history of marginally improving drugs and then charging higher prices for the new versions. And doctors, who have little info about how patients pay for drugs, often prescribe what is seen as the latest and greatest, even if the extra benefit is small.</p><h2>This is competition?</h2><p>In most industries, competition drives down prices. But the market for insulin looks more like airline tickets. When one company raises the price, the others quickly follow. And in some cases the companies even seem to increase prices simultaneously.</p><p>Look at this chart featuring two similar short-acting insulins: Eli Lilly and Co.'s Humalog and Novo Nordisk's Novolog. The prices, gathered by Truven Health Analytics, are in such lockstep that you can barely see both trend lines.</p><p><div class="KonaFilter image-container display-table"><div><div class="image on-image"><p class="source"><span>Andy Kiersz/Business Insider</span></p></div><p></p></div></div></p><p>It's a similar story with long-acting drugs like Sanofi's Lantus and Novo Nordisk's Levemir.</p><p><div class="KonaFilter image-container display-table"><div><div class="image on-image"><p class="source"><span>Andy Kiersz/Business Insider</span></p></div><p></p></div></div></p><p>All these drugs serve similar purposes and have seen similar price hikes.</p><p>What's missing in the marketplace - despite insulin's age - is generic competition.</p><p>Unlike chemically derived drugs like statins to lower cholesterol, or pain medication like ibuprofen, insulin is made of living cells. The industry calls it a "biologic" product. It's a lot more complicated to manufacture.</p><p>A "generic" version of insulin would be something called a <a href="http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/ucm241718.htm">biosimilar</a>, which is riskier to make. The drugs might have different reactions in your body.</p><p>So that's left the industry to three main players: Eli Lilly and Company, Novo Nordisk, and Sanofi Aventis.</p><h2>The big 3</h2><p>The companies do have competing drugs. For example, Humalog (Lilly's) and Novolog (Novo Nordisk's) are the two most prescribed short-acting insulins, while both Novo Nordisk and Sanofi make long-acting insulins (Levemir and Lantus).</p><p>But instead of driving prices down, the competitors appear to increase prices step-by-step (which is why the charts above look like a staircase), something the industry calls "<a href="http://www.bloomberg.com/news/articles/2015-05-06/diabetes-drugs-compete-with-prices-that-rise-in-lockstep">shadow pricing</a>." It's not just the insulin market that is doing this: The same thing happened with the <a href="http://www.forbes.com/sites/matthewherper/2016/08/30/the-consumer-rip-off-at-the-heart-of-the-epipen-scandal/#359709332a87">EpiPen market when a competitor came in around 2013</a> and with <a href="http://www.npr.org/sections/health-shots/2015/05/25/408021704/multiple-sclerosis-patients-stressed-out-by-soaring-drug-costs">multiple-sclerosis drugs</a>.</p><p>Ashleigh Koss, a spokeswoman for Sanofi, told Business Insider that Lantus had not had a price increase since November 2014 in the US. "In fact, because of aggressive discounting and rebates to insurance plans, <a href="http://www.businessinsider.com/scrutiny-express-scripts-pbms-drug-price-fury-2016-9">PBMs</a>, and government programs, the net prices of Lantus over the cumulative period of the last five years actually went down," she said.</p><p>When asked about pricing, Sanofi, Lilly and Novo Nordisk all highlighted discounts they provide, and also pointed the finger at health insurers.</p><p>"We know that many Americans with diabetes struggle to pay for their healthcare and, in some cases, this includes paying for medicines produced by us," Ken Inchausti, a spokesman for Novo Nordisk, told Business Insider in an email. "High deductible plans are still growing segment of all insurance plans. In addition to the significant rebates we provide insurance plans (including those who offer high deductible plans) to secure formulary positions, we fund co-pay cards and vouchers that commercially-insured patients can use for up to two years to offset those out-of-pocket costs they're incurring."</p><p>And while the drugs themselves might not change, the facilities in which they are made and the ways the insulin can be delivered have been upgraded. Gregory Kueterman, a spokesman for Lilly told Business Insider that the company spent billions of dollars on eight facilities that are used to produce and package insulin.</p><p>"We're spending a considerable amount of time studying this issue internally and talking to experts externally in this space. ... There are no quick and easy answers, because the system is complex and complicated," Kueterman said. "Even just simply lowering prices, while that seems like an easy answer, it wouldn't necessarily lower the prices of the high-deductible plan. They'd have to keep paying till they hit that deductible."</p><h2>Anxiety and answers</h2><p>The high prices don't affect all patients. Diabetes tends to be a condition that is well covered by insurers in comparison with other chronic diseases, like for example, <a href="http://www.nytimes.com/2015/07/24/us/kentucky-struggles-to-contain-hepatitis-c-among-young-drug-users.html">hepatitis C</a>. And many of the people living either with diabetes or with kids who have diabetes called themselves "blessed" to be able to manage the cost of care. For some, their copays were only $40 a month, and some kids were even covered under state plans.</p><p>But that doesn't keep parents from worrying about what happens once their kids age out of the state programs or out of their parents' insurance. Carole Andrew, a mother whose 18-year-old son learned he had diabetes a year ago, used the financial gravity of how much insulin costs to make sure her son takes his insulin.</p><p>"He wasn't as careful until I showed him the prices. It had a real impact," she said. Now that he knows how much it costs, he's been better about managing his blood-sugar levels.</p><p>Jessica Parkes, a 29-year-old who learned she had Type 1 diabetes when she was 20, found herself going into credit-card debt to pay for her supply of insulin. She had lost her job, she recalled, and her <a href="http://www.businessinsider.com/scrutiny-express-scripts-pbms-drug-price-fury-2016-9">pharmacy benefit manager</a> asked her to pay $400 in 2013 for a 90-day supply of insulin at a time when she didn't have health insurance. So she put it on her credit card and paid it off when she could. "I need my insulin to work and pay for the things I need," she said. "So I made my own payment plan."</p><p>The cost conversation could be entirely different by the time some of these kids have to leave their parents' insurance. Already, a drug called Basaglar is set to launch in the US in <a href="http://us.boehringer-ingelheim.com/news_events/press_releases/press_release_archive/2015/12-16-2015-fda-approves-basaglar-insulin-glargine-injection-long-acting-insulin-treatment.html">December</a> as an alternative to Lantus.</p><p>Although we won't know the price until it's announced later this year, it's unlikely to be <a href="http://www.businessinsider.com/what-is-a-biosimilar-and-how-does-it-work-2015-12">significantly cheaper</a>.</p><p>But in the end, this isn't a disease these kids and young adults will outgrow. There will always be a need to get insulin in their bodies, no matter the method or price.</p><p>"What makes me angry is that people are taking advantage," LePere said. "They know that we will do anything, I will do anything, to make sure my son has medicine the rest of his life."</p>    <div class="margin-top">        <h3>NOW WATCH: <a href="http://www.businessinsider.com/new-alien-megastructure-star-discovered-epic204278916-2016-9">Astronomers discovered a second 'alien megastructure' star that's even stranger than the first one</a></h3>        <div>            <div>        <div class="ooyala-video-player" data-video-autoplay="false" data-video-id="B1eG9zNTE6groKq5BMRrer_ocJMSx9Nd" data-player-variable="ooyalapopvideo" id="ooyalaplayer_popvideo" style="width:1280px;height:720px"></div>        </div>        </div>            </div>

A 93-year-old drug that some children can't live without tells us everything that's wrong with American healthcare

<p><div class="image-container float_right" style="width:400px"><div class="image"></div><p class="source">By Justin Sullivan/Getty Images</p></div><keyword id="6354630" type="PERSON" weightage="60" keywordseo="Mark-Zuckerberg">Mark Zuckerberg</keyword> and his wife Priscilla Chan were two of the most charitable Americans last year, second only to Warren Buffet.</p>
<p><a href="http://allfacebook.com/zuckerberg-chan-philanthropy-2012_b110532">Zuckerberg and Chan donated about $500 million</a> worth of Facebook stock (18 million shares) in 2012. They gave it all to the Silicon Valley Community Foundation.</p>
<p>It was Zuckerberg's largest donation to date. In 2010 he gave Newark, New Jersey schools $100 million to further education efforts there.</p>
<p>Warren Buffet donated about $3.6 billion last year. His money went towards the Howard G. Buffett Foundation, NoVo Foundation, and the Sherwood Foundation. But then, his fortune is much more sizeable than Zuckerberg's: $46 billion versus $9.6 billion.</p>

Mark Zuckerberg Was The 2nd Most Charitable American Last Year

<p><em>Welcome to Digital Health Briefing, the newsletter providing the latest news, data, and insight on how digital technology is disrupting the healthcare ecosystem, produced by Business Insider Intelligence.</em></p><p><a href="http://www.businessinsider.com/intelligence/digital-health-briefing?IR=T"><strong>Sign up and receive Digital Health Briefing free to your inbox.</strong></a></p><p><em>Have feedback? We'd like to hear from you. Write me at:</em> <a href="mailto:lbeaver@businessinsider.com"><em>lbeaver@businessinsider.com</em></a></p><p><strong>COMCAST TAKES A STAB AT HEALTHCARE COMMUNICATIONS:</strong> Comcast plans to enter the healthcare market with the lofty goal of improving the efficiency and consumer experience of care delivery, <a href="http://www.healthcareitnews.com/news/comcast-partners-independence-health-create-digital-health-company">according</a> to CNBC. The media giant is partnering with Independence Health Group - one of the largest Blue Shield insurers in the US - to develop an open source tech and communications platform that will allow patients to access their data throughout their healthcare journey. The venture will pilot in Philadelphia before a nationwide rollout in the second half of 2019.</p><p>While specific details about what the platform will do to support consumers are scarce, it's expected that it will house an educational component and telemedicine capabilities, <a href="https://www.investopedia.com/news/comcast-independence-health-new-partnership/">according</a> to Investopedia. At first, the platform will target individuals who are experiencing well-known health conditions, such as knee surgery, following them throughout the regimen of pre-op, post-op, and maintenance.</p><p><strong>Each company stands to gain from the independently run digital health firm.</strong> For Comcast - the largest cable and broadband provider in the US - the venture will enhance the Comcast experience by providing customers with access to basic healthcare information that they'd otherwise have to go elsewhere for. Meanwhile, Independence benefits from providing its customers with a more transparent, efficient, and customer-first health offering.</p><p><strong>Comcast is just the latest in a string of non-healthcare companies entering the market to solve the US healthcare crisis.</strong> Health systems and insurers are looking to tech companies' solutions to help boost customer satisfaction, cut costs, and improve data interoperability.</p><ul><li><strong>Amazon</strong> <a href="http://www.businessinsider.com/digital-health-briefing-amazon-sets-aside-drug-ambitions-google-considers-bid-for-nokias-digital-health-business-optum-revenue-hits-double-digits-2018-4">appears</a> to be building out a full healthcare ecosystem in an effort to become a one-stop shop for health systems and patients. The company introduced several <a href="http://www.businessinsider.com/digital-health-briefing-amazon-to-enter-major-healthcare-partnership-apple-watch-aids-in-treating-depression-ibm-watson-shows-its-power-in-cancer-study-2017-11">cloud</a> and <a href="http://www.alexadiabeteschallenge.com/">voice</a> initiatives, as well as supplying medical devices to clinics and small hospitals, and <a href="http://www.businessinsider.com/digital-health-briefing-amazon-berkshire-jpmorgan-to-launch-healthcare-company-mobile-tech-is-transforming-hospitals-omada-health-launches-new-trial-2018-1">partnered</a> with JPMorgan and Berkshire to start its own health company.</li><li><strong>Apple</strong> <a href="http://www.businessinsider.com/why-apples-moving-into-the-health-records-market-2018-1">updated</a> its Health app to make it easier for some US iPhone users to record, store, and share their health data with providers and insurers. At the end of March, the company <a href="http://www.businessinsider.com/digital-health-briefing-oscar-health-surpasses-3-billion-valuation-apple-health-app-adds-27-more-hospitals-lyft-expands-its-nemt-footprint-2018-3">announced</a> an additional 27 health systems were ready to use the service, bringing the total number of partnered health systems to 39</li><li><strong>Google</strong> <a href="http://www.businessinsider.com/digital-health-briefing-google-targets-hospital-interoperability-lyft-allscripts-partner-for-medical-transport-samsung-health-gets-diabetes-program-2018-3/">introduced</a> the Cloud Healthcare API during HIMSS18 in March, which aims to make it easier for health organizations to collect, store, and access health data. The internet giant then <a href="http://www.businessinsider.com/digital-health-briefing-google-ama-launch-interoperability-challenge-doctor-on-demand-rolls-out-location-based-lab-tests-allscripts-careport-bolster-care-coordination-solution-2018-4">partnered</a> with the American Medical Association to run an interoperability challenge.</li></ul><p><strong>Comcast and Independence view the tech companies' healthcare ambitions as opportunities, rather than threats to their initiative.</strong> The two firms aim to have tech companies use the digital health platform to house their services and features.</p><p><em>Enjoy reading this briefing?  <a href="http://www.businessinsider.com/intelligence/digital-health-briefing">Sign up</a> and receive Digital Health Briefing to your inbox.</em></p><p><strong>FDA UNVEILS FIVE-POINT PLAN FOR MEDICAL DEVICE SAFETY:</strong> As a part of its 2019 budget request last week, the US Food and Drug Administration (FDA) <a href="https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm604672.htm">released</a> a five-point plan to improve medical device safety. The administration has been working to <a href="http://www.businessinsider.com/digital-health-briefing-anthem-prepares-to-launch-digital-health-hub-fda-to-clarify-requirements-for-medical-devices-vr-finds-footing-in-healthcare-2017-10" target="_blank" rel="noopener">streamline</a> the process of getting new digital health tech to market. For example, there's the updated Medical Device User Fee Agreement (MDUFA), or the CHRONIC Care Act, which expands the reach and purview of mobile solutions. And as new medical devices and solutions are brought to market, the FDA is now focusing on safety enhancements to keep pace with emerging cyber threats. A part of the plan is the consolidation of the premarket and postmarket offices within its medical device center to better align the development and maintenance of medical devices. The FDA is also considering a requirement for device makers to adopt policies and procedures to disclose device vulnerabilities as they occur. Looking ahead, the agency will look at developing scientific premarket toolkits for developers that will better assure users that the devices are meeting the FDA's safety standards.</p><p><strong>NEW STUDY ADDS WEIGHT TO BENEFITS OF REMOTE PATIENT MONITORING:</strong> A study by a team of researchers from the University of Madrid has shown that 24-hour blood-pressure monitoring is a better predictor of cardiovascular and all-cause mortality than single blood-pressure tests in clinics, MobiHealthNews <a href="http://www.mobihealthnews.com/content/study-64000-patients-shows-value-24-hour-blood-pressure-monitoring">reports</a>. The study offers more validation for the use of remote patient monitoring (RPM) wearables and devices to provide clinicians with fuller, more accurate patient data. And while such devices aren't yet a common part of standard healthcare, more and more research and clinical trials are underway to demonstrate the usefulness of continuous RPM, especially for things like chronic illnesses. Chronic illnesses are the biggest strain on the healthcare industry, <a href="http://www.ahrq.gov/sites/default/files/wysiwyg/professionals/prevention-chronic-care/decision/mcc/mccchartbook.pdf">accounting</a> for 86% of the $2.7 trillion spent in annual health care costs in the US in 2014 alone. Aging populations and the ongoing decline in direct care workers means this strain is only getting worse. Wearable adoption is slowly taking off as consumers begin to see the benefits of quantifying their health data by monitoring steps and heart rates, for example. This is particularly attractive to younger generations, with 67% of US millennials saying they would wear a wearable device in exchange for personalized insurance, <a href="https://intelligence.businessinsider.com/post/the-us-telehealth-market-report-the-market-drivers-and-threats-and-opportunities-for-incumbents-and-newcomers-2018-2">according</a> to the 2018 Business Insider Intelligence Insurance Technology Study. </p><p><div class="KonaFilter image-container display-table click-to-enlarge"><div><div class="image on-image"><a title_source="Business Insider Intelligence" title_caption="" class="zoomin" href="https://static-ssl.businessinsider.com/image/5addfad019ee861d008b463b-960/bii willingness to use wearable for personal plan.png"><span class="sprites click-to-enlarge-icon" title="Click to enlarge"></span></a><p class="source"><span>Business Insider Intelligence</span></p></div><p></p></div></div></p><p><strong>IN OTHER NEWS:</strong></p><ul><li><strong>Two English health trusts</strong> have begun using a link up that allows their physicians to access patient data that's held within each other's electronic patient system, Digital Health <a href="https://www.digitalhealth.net/2018/04/gde-live-link-up-epr/">reports</a>. The West Suffolk Hospital NHS Foundation Trust and the Cambridge University Hospitals NHS Foundation Trust are global digital exemplars of NHS England's flagship initiative that supports advanced digital trusts to pave the way for those less advanced.</li><li><strong>Samsung</strong> is reportedly <a href="http://www.businessinsider.com/digital-health-briefing-amazon-sets-aside-drug-ambitions-google-considers-bid-for-nokias-digital-health-business-optum-revenue-hits-double-digits-2018-4">competing</a> with Google in a bid to acquire Nokia's digital health business, <a href="https://www.phonearena.com/news/Samsung-Google-bidding-Nokia-Health_id104266">according</a> to Phone Arena. Nokia has been <a href="http://www.businessinsider.com/digital-health-briefing-nokia-rethinks-its-digital-health-business-intelligent-cds-platform-gets-fda-approval-new-ata-ceo-aims-to-expand-telehealth-awareness-2018-2">seeking</a> a resolution to its flailing digital health arm woes since Q4 2017 and a slew of tech companies are vying to snatch up the segment to strengthen their own offerings.</li><li><strong>Sempre Health, </strong>a medication management startup, is collaborating with drug maker Novo Nordisk, to improve adherence rates in diabetics, MedCity News <a href="https://medcitynews.com/2018/04/novo-nordisk-collaborates-with-healthcare-startup-to-incentivize-diabetes-medication-adherence/">reports</a>. Sempre Health will send participants a text message that offers a discount if the consumer picks up their medication on a certain day.</li></ul> <p class="tagline"><a href="http://www.businessinsider.com/intelligence/top-5-trends-shaping-the-future-of-digital-health?IR=T&amp;utm_source=businessinsider&amp;utm_medium=ctgr&amp;utm_term=ctgr_leadgen&amp;utm_content=digitalhealth_ctgr_leadgen&amp;utm_campaign=digitalhealth_ctgr_leadgen_5-trends"></a></p>

DIGITAL HEALTH BRIEFING: Comcast will launch a digital health platform - FDA's five-point plan for device security - New study adds weight to remote patient monitoring

<p></p><div class="KonaFilter image-container display-table float_right"><div><div class="image on-image"></div><p></p></div></div>Hillary Clinton says she had a "<a href="http://www.huffingtonpost.com/2014/07/05/hillary-clinton-thrive_n_5560491.html">restful</a>" time following her tenure as Secretary of State, but that doesn't mean she didn't make a lot of money.<p>During that time, she made nearly $12 million by charging fees that topped $335,000 for dozens of speeches<span style="line-height: 1.5em;">.</span></p><p>Clinton's speaking fees shed light on the industries willing to shill out big bucks for a few minutes with the former Secretary of State.</p><p><span>As the&#xa0;</span><a href="http://www.washingtonpost.com/graphics/politics/clinton-speeches/">Washington Post</a><span>&#xa0;notes</span><span>, a significant chunk of the money that Clinton made from speeches came from tech companies.&#xa0;eBay shilled out $315,000 for a speech that last 20 minutes, while Cisco paid $325,000 for Clinton to sit onstage with the company's CEO.&#xa0;</span><span>Salesforce.com brought Clinton back for multiple events.</span></p><p>And for discount spenders, Clinton offered a reduced price for remote addresses via satellite video. The former Secretary of State charged some of her lowest speaking fees to the California Medical Association and Novo Nordisk for video speeches.</p><p>Oddly, a<span style="line-height: 1.5em;">&#xa0;number of news organizations such as the </span><a href="http://www.washingtonpost.com/graphics/politics/clinton-speeches/">Washington Post</a><span style="line-height: 1.5em;">, </span><a href="http://time.com/3889577/hillary-clinton-paid-speeches-lobbyists-influence/">Time</a><span style="line-height: 1.5em;"> and </span><a href="http://www.politico.com/story/2015/05/bill-and-hillary-clinton-made-roughly-25-million-in-speeches-since-2014-118009.html">Politico</a><span style="line-height: 1.5em;">&#xa0;that checked out the same financial disclosure form couldn't seem to agree on the numbers.</span></p><p>The Washington Post and Politico agree on Clinton's speaking fee from Qualcomm, which both reported as $335,000. That's not the number that Time saw - the magazine reported that Clinton made $125,000 on the speech.</p><p>How much did Clinton make from the National Automobile Dealers Association? Politico says $325,000, but Time and the Washington Post report that the number is $225,000.</p><p>The publications also seem at odds over how much Clinton got paid for a speech at Deutsche. Time and Politico report $280,000, but the Washington Post claims that the number is $260,000</p><p>The discrepancies seem to be the result of the filing itself. The financial disclosure form, released online by the New York Times, is slightly blurry when users zoom in.</p><p><span style="line-height: 1.5em;">Here's Business Insider's take on the list, ranked from highest to lowest speaking fees:</span></p><div><div></div></div><p class="embed-spacer"></p>    <div class="margin-top">        <h3>NOW WATCH: <a href="http://www.businessinsider.com/ted-cruz-remarks-presidential-candidacy-announcement-republican-2016-2015-3">Here's what Senator Ted Cruz said about Hillary Clinton and President Obama hours before announcing his presidential candidacy</a></h3>        <div>            <div>        <div class="ooyala-video-player" data-video-autoplay="false" data-video-id="kwbTc1dDr9e48v5ztaofYcTYVcbjpTi3" data-player-variable="ooyalapopvideo" id="ooyalaplayer_popvideo" style="width:1280px;height:720px"></div>        </div>        </div>            </div>

Here are all the six-figure speaking fees that Hillary Clinton received after leaving the State Dept.

<p><div class="KonaFilter image-container display-table"><div><div class="image on-image"><p class="source"><span>Sky News/Reuters</span></p><p class="caption">Bill Browder's advocacy for the Magnitsky Act poses a serious challenge to Putin's foreign fortune.</p></div><p></p></div></div></p><ul><li><strong>Vladimir Putin mentioned Bill Browder's name at his joint press conference with Trump in Helsinki on Monday.</strong></li><li><strong>Browder is a financier behind the Magnitsky Act, which authorizes governments to sanction Russian human rights offenders and freeze their assets.</strong></li><li><strong>The act is believed to threaten much of </strong><strong>Putin's personal wealth, which is tied up in foreign assets.</strong></li><li><strong>Putin offered to allow US officials to interview Russians suspected of interfering with the 2016 elections in exchange for interviewing people close to Browder.</strong></li></ul><p>Vladimir Putin spontaneously singled out one man who poses a unique threat to the Russian leader's massive fortune at Monday's press conference, and it may hint at one of Putin's greatest weaknesses.</p><p>The man in question is Bill Browder, a US-born British financier behind the Magnitsky Act, which authorizes governments to sanction human rights offenders in Russia, freeze their foreign assets, and ban them from entering the signing country.</p><p>Many of these Russians are tied to Putin's government, and <a href="https://www.theatlantic.com/international/archive/2017/07/magnitsky-act-kremlin/535044/">much of Putin's personal wealth</a> is believed to be tied up in those foreign assets.</p><p>On Monday, Putin suggested allowing US officials to interview Russians suspected of interfering with the 2016 elections in exchange for interviewing people close to Browder.</p><p><div class="KonaFilter image-container display-table"><div><div class="image on-image"><p class="source"><span>Chris McGrath/Getty Images</span></p></div><p></p></div></div></p><p>The Russian president told reporters, while standing alongside Donald Trump:</p><p style="padding-left: 30px;">"We can meet you halfway. We can make another step. We can actually permit representatives of the United States, including the members of this very commission headed by Mr Mueller, we can let them into the country. They can be present at questioning.</p><p style="padding-left: 30px;">"In this case, there's another condition. This kind of effort should be mutual one. Then we would expect that the Americans would reciprocate. They would question officials, including the officers of law enforcement and intelligence services of the United States whom we believe have something to do with illegal actions on the territory of Russia. And we have to request the presence of our law enforcement.</p><p style="padding-left: 30px;">"For instance, we can bring up Mr Browder in this particular case. Business associates of Mr Browder have earned over $1.5 billion in Russia. They never paid any taxes. Neither in Russia nor in the United States. Yet, the money escapes the country. They were transferred to the United States. They sent huge amount of money, $400 million as a contribution to the campaign of Hillary Clinton.</p><p style="padding-left: 30px;">"Well, that's their personal case. It might have been legal, the contribution itself. But the way the money was earned was illegal. We have solid reason to believe that some intelligence officers, guided these transactions. So we have an interest of questioning them.</p><p style="padding-left: 30px;">"That could be a first step. We can extend also it. Options abound. They all can be found in an appropriate legal framework."</p><p><div class="KonaFilter image-container display-table"><div><div class="image on-image"><p class="source"><span>Getty Images/ AFP/ Bertrand Guay</span></p><p class="caption">Browder.</p></div><p></p></div></div></p><h2>Putin is "seriously rattled"</h2><p>Browder wrote in response that Putin's offhand remark showed he was "seriously rattled" by the Magnitsky Act's growing popularity around the world.</p><p><a href="http://time.com/5340545/bill-browder-vladimir-putin-magnitsky-act-donald-trump/">He wrote in Time</a>: "Putin almost never utters the names of his enemies - except for mine, which he lately seems to utter at every opportunity. To my mind, this can only mean that he is seriously rattled."</p><p>The Obama administration signed the act into law in 2012, while other countries including the UK, Canada, Estonia, Latvia, and Lithuania, have signed similar versions of the act.</p><p>Britain <a href="https://uk.reuters.com/article/uk-britain-russia-magnitsky/mps-back-magnitsky-amendment-on-sanctions-for-human-rights-abuses-idUKKBN1I24B9">signed a second version</a> of the Magnitsky Act in May, following the <a href="http://uk.businessinsider.com/category/sergei-skripal">poisoning of former Russian spy Sergei Skripal</a> in southern England, that would allow the government to impose sanctions on human rights violators. A previous version of the act from 2017 only allowed the government to freeze the assets of human rights violators.</p><p>Browder <a href="https://www.washingtonpost.com/news/josh-rogin/wp/2018/07/16/putin-just-confirmed-the-human-rights-sanctions-are-working/">told The Washington Post</a> on Monday: "This is an incredibly powerful tribute to the power of the Magnitsky Act. This shows I've found Putin's Achilles' heel, that he's very rattled by it.</p><p>"For a guy who's supposed to be a former KGB spy, he's got a terrible poker face."</p><p>The act was named after Browder's lawyer, Sergei Magnitsky, who Browder says was put in pretrial detention, tortured, and killed in Russian custody in 2009..</p><p><div class="KonaFilter image-container display-table"><div><div class="image on-image"><p class="source"><span>REUTERS/RIA Novosti/Pool/Alexei Nikolsky</span></p><p class="caption">Then-Secretary of State Clinton and Putin in the Novo-Ogaryovo presidential residence in March 2010.</p></div><p></p></div></div></p><h2>Putin's 'pants on fire' Clinton allegation</h2><p>Putin's claim that Browder donated $400 million to Clinton's campaign was baseless, <a href="http://www.politifact.com/truth-o-meter/statements/2018/jul/16/vladimir-putin/putins-pants-fire-claim-about-400-million-donation/">PolitiFact</a> and <a href="https://www.nytimes.com/2018/07/16/world/europe/putin-bill-browder-magnitsky-investor.html">The New York Times</a> both reported.</p><p>As a British citizen, Browder cannot legally donate to US candidates in a personal capacity.</p><p>However, the New York-based Ziff Brothers investment firm, with whom Browder has worked, previously donated to Clinton campaign, Democratic National Committee, and the Clinton Foundation - but those sums totaled about $1.1 million, Politifact said.</p><p>"The exaggeration is so great, we rate this claim Pants on Fire," the fact-checking site said.</p><p>Browder, who was at one point Russia's largest foreign investor, was deported from Russia in 2005 after exposing corruption in the country. Russian authorities called him a threat to national security, and a Russian court sentenced Browder in absentia to nine years in prison on fraud and tax evasion last year.</p><p>Moscow has issued six requests to Interpol to arrest and extradite him, <a href="https://twitter.com/Billbrowder/status/1001755983075577856">Browder previously said</a>, but the agency has <a href="https://www.telegraph.co.uk/news/uknews/law-and-order/10082582/Interpol-makes-the-world-a-safer-place.html">routinely ignored</a> those requests in the past. Browder was briefly arrested in Spain in May, but neither Interpol nor the Spanish National Police denied that it was due to a Russian extradition order.</p>       <div class="margin-top">        <h3>NOW WATCH: <a href="http://www.businessinsider.com/north-korean-defector-calls-out-kim-jong-un-terrorist-singapore-summit-2018-6">North Korean defector: Kim Jong Un 'is a terrorist'</a></h3>        <div>                    </div>    </div>

Putin hinted he wanted Trump to give him access to one man - and it reveals his greatest weakness

<p><div class="KonaFilter image-container display-table float_right"><div><div class="image on-image"></div><p></p></div></div>Isabel dos Santos, the daughter of the president of Angola and Africa's <a href="http://www.forbes.com/sites/kerryadolan/2013/08/14/how-isabel-dos-santos-took-the-short-route-to-become-africas-richest-woman/">youngest and only female billionaire</a>, is sending the share prices of two of Portugal's biggest banks surging.</p><p><a href="http://uk.reuters.com/article/2015/03/03/portugal-banks-ma-idUKL5N0W52HN20150303?feedType=RSS&amp;feedName=rbssFinancialServicesAndRealEstateNews">A source told Reuters that dos Santos wrote to the CEO Spain's Caixabank</a>, suggesting a merger of two Portuguese banks, Millennium BCP and Banco BPI.</p><p>Caixabank already owns nearly half of Banco BPI, and dos Santos owns nearly a fifth. A merger between the two was suggested back in 2007, but never saw the light of day.</p><p>Both banks are both enjoying the news. As of 3:15 p.m. GMT (10:15 a.m. ET) <span style="line-height: 1.5em;">Banco BPI shares are up by 8.24% to their highest level since December, and Millennium BCP is up 3.7% to levels last seen in November. </span></p><p><a href="http://www.ft.com/fastft/285882/isabel-dos-santos-proposes-merger-of-bcp-bpi">The Financial Times notes</a> that the new entity could not only be Portugal's biggest lender, but also be majority Angolan-owned.</p><p>Here's Peter Wise at FastFT:</p><p style="padding-left: 30px;">Sonangol, Angola's state oil company, is by far the biggest shareholder in BCP with 20 per cent. If a BCP-BPI merger were to go ahead, Angolan investors would probably be the biggest shareholders in the new entity.</p><p style="padding-left: 30px;">However, a potential merger between BCP and BPI would have to clear massive regulatory hurdles, given that both BCP and BPI received state aid during Portugal's recent bailout and that BPI is seen as a leading contender to buy Novo Banco, the "good bank" created out of the ruins of Banco Espírito Santo, which collapsed last year. </p><p><span>Portugal's banks often have major business interests in Angola, which was a Portuguese colony until 1975. </span><span style="line-height: 1.5em;">So Angolans are pretty used to Portuguese business interests affecting their own country. But it's not quite as often that an Angolan billionaire reaches back in the other direction. </span></p>    <div class="margin-top">        <h3>NOW WATCH: <a href="http://www.businessinsider.com/largest-ice-glacier-calving-filmed-2015-1">This Video Of The Largest Breakage Of Ice From A Glacier Ever Filmed Is Absolutely Frightening</a></h3>        <div>            <div>        <div class="ooyala-video-player" data-video-autoplay="false" data-video-id="NqbHJucjpzcqR3obKs3FqeMQRi8yolxr" data-player-variable="ooyalapopvideo" id="ooyalaplayer_popvideo" style="width:1280px;height:720px"></div>        </div>        </div>            </div>

Africa's only female billionaire is sending Portuguese bank shares through the roof

<p><div class="KonaFilter image-container display-table float_right"><div><div class="image"></div><p></p></div></div></p><p>The rise of leftist governments in Latin America in the early 2000s know as the "pink tide" was, in part, a response to US involvement in the region in the 1960s, 70s, and 80s when the Cold War was raging strong. Military interventions, regime changes, and proxy battles that have faded from memory in US live on in the minds of Latin America populists, and Chavez was chief among them.</p><p>He was joined in his anti-Americanism by leaders in Ecuador and Nicaragua, and to a lesser extent Bolivia and Argentina, among South America's larger countries. These countries provide Russia with diplomatic support, they champion Russia in state media, and more importantly, they grant Russia access to their ports and airspace.</p><p>One of the problems with that, according to security analyst Douglas Farah, is that where Russia goes, Russian organized crime inevitably follows. Venezuelan President Nicolas Maduro has kept a great home for it too - carrying on the tradition of mixing criminal activity with politics established by his predecessor.</p><p><div class="KonaFilter image-container display-table"><div><div class="image on-image"></div><p></p></div></div></p><p><span>"The Maduro administration is the central component to a multi-state ongoing criminal enterprise, carried out with Iran and a growing Russian presence whose primary strategic objective is to cling to power by whatever means necessary and harm the United States and its allies," said Farah in a hearing with the Senate foreign relations committee this month.</span></p><div class="page" title="Page 2"><div class="layoutArea"><div class="column"><p>As Russia's presence in the region grows, it's actions get bolder. On Friday, Alexander Fomin, the head of the Federal Service for Military-Technical Cooperation, <a href="http://news.yahoo.com/russia-denies-talks-argentina-leasing-jets-102502136.html">denied</a> reports that Russia is in talks with Argentina over offering Argentina a batch of 12 Su-24 bombers on lease.</p><p>"Regrettably, the issue isn't being discussed," he said, "but we are ready to discuss it."</p><p><div class="KonaFilter image-container display-table float_right"><div><div class="image on-image"></div><p></p></div></div>The US, for its part, is not ready for this incursion, according to the military's Southern Command.</p><p>The Obama administration's policy in the region has been to secure a perimeter around the United States and support allies like Brazil, Colombia, Chile, Panama, and El Salvador as they try to rid their countries of organized crime and violence.</p><p>"Because of the U.S. presence in countries abutting Russia, Russia may be looking to do the same in our region," Carlos Rivera Bianchini, the president of the Foundation for Peace and Democracy Costa Rica, <a href="http://www.mcclatchydc.com/2015/03/23/260684/russias-return-to-nicaragua-worrying.html">told</a> McClatchy recently.</p><p>Southern Command has traditionally been the lowest priority for the military, and cut its budget by 20% over the last year.</p><p>And with Russia's Latin America resurgance, that isn't enough anymore.</p><p>"Our friends across the region are committed to winning back their streets, indeed their countries, from criminal gangs and drug traffickers, and doing so while protecting human rights. They are ready and willing to partner with the United States, and they are eager for expanded cooperation and increased learning and training opportunities with the U.S. military," said Tovo.</p><p><div class="KonaFilter image-container display-table float_right"><div><div class="image on-image"></div><p></p></div></div>"But they are frustrated by what they perceive as the low prioritization of Latin America on our national security and foreign policy agendas, which is especially puzzling given the shared challenge of transnational organized crime... Mr. Chairman, Members, the truth is we are managing to keep the pilot light of U.S. military engagement on in the region-but just barely." <span> </span></p></div></div></div><p> </p>    <div class="margin-top">        <h3>NOW WATCH: <a href="http://www.businessinsider.com/how-to-data-vlookup-excel-microsoft-2015-1">If you're not using this data-searching trick in Excel, you're wasting lots of time</a></h3>        <div>            <div>        <div class="ooyala-video-player" data-video-autoplay="false" data-video-id="NkZDIzczpfOkg-XdS8O7coifW4uffnoT" data-player-variable="ooyalapopvideo" id="ooyalaplayer_popvideo" style="width:1280px;height:720px"></div>        </div>        </div>            </div>

It's time to start worrying about what Russia's been up to in Latin America

<p></p><div class="KonaFilter image-container display-table float_right"><div><div class="image on-image"></div><p></p></div></div>Child prodigies have long been a riddle.<p>Two academics, David Feldman and Martha Morelock, once complained-only somewhat facetiously-that "divine inspiration, reincarnation, or magical incantation" were the best explanations for child prodigies that <keyword id="41551" type="ENTERTAINMENT" weightage="100" keywordseo="science">science</keyword> had to offer.</p><p>But the psychologist Joanne Ruthsatz developed a startling hunch after a chance encounter with a music prodigy's autistic cousin: &#xa0;Could autism have something to do with prodigious talent?</p><p>The answer seems to be yes. Child prodigies don't typically have autism.</p><p>But many prodigies have autistic relatives. Brothers. Sisters. Uncles. Grandmothers. Some have autism in every twig and branch of the family tree.</p><p>The prodigies themselves-all of them-have autistic characteristics, such as extraordinary attention to detail and a tendency toward obsession.</p><p>They draw on these traits to rocket to the top of their fields; these attributes are essential to their success.</p><p>Ruthsatz and a research team at The Ohio State University have even found evidence that prodigies and autists may have a genetic link in common, a mutation on chromosome 1 that some prodigies and autists (but not their non-prodigious, non-autistic relatives) share.</p><p>This connection is fascinating; it offers an unexpected perspective on the riddle of the prodigies' talent and an intriguing take on what drives children to hone their skills with laser-like focus and intensity. &#xa0;</p><p>But understanding child prodigies' abilities is only the first step; the next is to find out whether studying this connection could improve our understanding of autism. Doing that requires investigating why it is that prodigies possess the strengths associated with autism but not the challenges.</p><p>The answer may be in the prodigies' genes.</p><p>The prodigies and the autists appear to share genes on chromosome 1-a common foundation. But it is likely that the two groups also have critical genetic differences.</p><p>What if there is something about the prodigies' genes that protects them from autism's social and communication deficits but leaves the heightened attention to detail, astounding memory, and passionate interests of autism in place?</p><p>If the prodigies and the autists share a genetic mutation and have important genetic differences, maybe studying the prodigies could unlock a piece of autism's infamously complex genetic architecture.</p><p>It could mean that a breakthrough in autism research will come not from studying autists, but from studying child prodigies.</p><p>This sort of thinking has begun to light other areas of medical research on fire.</p><p>For decades, scientists sought to learn more about medical conditions ranging from diabetes to heart disease by studying those who have those conditions.</p><p>But recently scientists have begun looking in the other direction for answers.</p><p>Instead of focusing solely on those who are sick, scientists have taken a keen interest in those who are well-especially those who are at high risk for a particular disease, due to genes, lifestyle, or both, but don't develop it.</p><p>The idea is that if the scientists can isolate whatever it is that protects these inexplicably healthy individuals from the disease in question, perhaps they can use that knowledge to help those who actually have the disease.</p><p>Scientists investigating HIV, for example, made a major breakthrough by studying high-risk individuals who never contracted the virus: they discovered a genetic mutation that protects against some strains of HIV, which ultimately led to the improvement of HIV treatments. &#xa0;</p><p>This beneficial mutation would never have been discovered, and the associated treatments likely wouldn't have been developed, if scientists hadn't scoured the DNA of people who were well. These inexplicably healthy but at-risk HIV subjects are the prodigies of the HIV world; researchers study them in an effort to help their "cousins"-those who contract the virus.</p><p></p><div class="KonaFilter image-container display-table"><div><div class="image on-image"></div><p></p></div></div>Such efforts to better understand those who are well have produced some spectacular results, but autism is not HIV. &#xa0;Not everyone agrees that scientists should try to "cure" autism in the same way they might try to cure diabetes or heart disease. Some advocates argue that we should view conditions like autism as neurological variations, not neurological disorders. Autism then is a distinct combination of strengths and weaknesses and a part of the individual's personhood.<p>From this perspective, focusing on the search for autism's genetic roots could be misguided (as could efforts to develop pharmaceutical treatments, which are often tied to this sort of work). Autists may not view their autism negatively. Autists also can and do make great contributions to society, and they may be able to do so not in spite of their autism but because of it.</p><p>And every dollar spent on analyzing genes is a dollar not spent on accommodations, support, and efforts to increase sensitivity that could help autists now. As Julia Bascom, deputy executive director of the Autistic Self Advocacy Network, put it, "The biggest barrier the autistic community faces is not our autism, but a society which is ignorant, unaccommodating, and often actively hostile to people who are different, people with disabilities, and autistic people."</p><p>Others are equally adamant about the necessity and urgency of finding effective ways to treat autism. It's a disorder, they believe, and parents should do all they can to help their children fight against it. Those who argue for acceptance over intervention, they often claim, are "high functioning": they don't appreciate the difficulties faced by those with more severe autism.</p><p>The rarity of child prodigies poses another difficulty for this kind of research, as scientists attempting to study prodigies' genes are stuck with a small sample size. Similar autism research has been done in genetics studies involving siblings of autists (the autists' genes are compared with those of their non-autistic siblings), and while this approach has helped identify autism-linked genes, it hasn't yielded any genetic variants that seem beneficial.</p><p>Autism has such complicated, knotty underlying genetics that it may not be possible to tease out anything useful.</p><p>"So far, none of these single-gene studies has given us anything that's in some sense actionable to say okay, we can take this, block that gene, or further goose up the effect of that gene, and it's gonna get us somewhere," Bruce Cuthbert, the acting director of the National Institute of Mental Health, said. "That just hasn't proven to be the case."</p><p>But that doesn't mean it's not worth exploring. The debate over the nature of autism is important and should be approached with great sensitivity, but you don't need to believe that autism should be "cured" to appreciate the power of studying those who aren't on the spectrum from a research perspective.</p><p>To this end, prodigies have something important in common with the high-risk but unaffected patients who helped transform HIV research.</p><p>Given their family histories, prodigies could be considered at high risk for autism, just as some people are at high risk for contracting HIV, and unlike the typically developing siblings of autists, the prodigies all demonstrate some truly extreme autism-linked behaviors and cognitive abilities. From this perspective, maybe the prodigies aren't just a marvelous curiosity. Maybe they are a potential Rosetta stone for some variations of autism.</p><p>The prodigy genetics research is ongoing. The Ohio State team still needs to pin down the chromosome 1 mutation shared by prodigies and autists. Ruthsatz is also collaborating with Guy Rouleau, the director of the Neuro (McGill University's neuroscience research hospital) and his colleagues in Canada to hunt for a de novo mutation that contributes to prodigious talent.</p><p>It's possible that neither team will find anything of interest to autism researchers, but it's also possible that they will.</p><p>It's only by actually studying child prodigies, a group long relegated to the research sidelines, that we'll find out. &#xa0;If the connection between prodigy and autism bears out, if prodigies really can point the way toward an improved understanding of autism, maybe child prodigies aren't so much a mystery anymore.</p><p>Maybe they're the beginning of an answer.</p><p><em>Reprinted from "<a href="http://www.amazon.com/Prodigys-Cousin-Family-Between-Extraordinary/dp/1617230189/ref=tmm_hrd_swatch_0?_encoding=UTF8&amp;qid=&amp;sr">The Prodigy's Cousin: The Family Link Between Autism and Extraordinary Talent</a>" by Joanne Ruthsatz and Kimberly Stephens with permission of Current, an imprint of Penguin Publishing Group, a division of Penguin Random House LLC. Copyright (c) Joanne Ruthsatz and Kimberly Stephens, 2016.</em></p>    <div class="margin-top">        <h3>NOW WATCH: <a href="http://www.businessinsider.com/when-buy-organic-produce-consumer-reports-2016-3">Here's when buying organic produce is a must and when it doesn't really matter</a></h3>        <div>            <div>        <div class="ooyala-video-player" data-video-autoplay="false" data-video-id="lpOTV0MTE65T-Y_xkbrIb9puU2zMfmL3" data-player-variable="ooyalapopvideo" id="ooyalaplayer_popvideo" style="width:1280px;height:720px"></div>        </div>        </div>            </div>

You Searched For "NoVo Foundation" and got 8 results

A 93-year-old drug that some children can't live without tells us everything that's wrong with American healthcare

Lydia Ramsey

Mark Zuckerberg Was The 2nd Most Charitable American Last Year

Alyson Shontell

DIGITAL HEALTH BRIEFING: Comcast will launch a digital health platform - FDA's five-point plan for device security - New study adds weight to remote patient monitoring

Laurie Beaver

Here are all the six-figure speaking fees that Hillary Clinton received after leaving the State Dept.

Maxwell Tani

Putin hinted he wanted Trump to give him access to one man - and it reveals his greatest weakness

Alexandra Ma

Africa's only female billionaire is sending Portuguese bank shares through the roof

Mike Bird

It's time to start worrying about what Russia's been up to in Latin America

Linette Lopez

Studying child prodigies could be the key to the autism breakthrough scientists have been waiting for

Joanne Ruthsatz and Kimberly …